| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:2104.)
© 2002 American Heart Association, Inc.
Basic Science Reports |
-Toxin
From the Department of Cardiothoracic and Vascular Surgery (D.P., J.M., M.D., H.O.) and Department of MedicineCardiology (M.S., U.B., J.M., H.D., M.B.), Johannes Gutenberg-University, Mainz, and Department of Medicine II (U.S., U.G., F.G., W.S.), Justus Liebig University, Giessen, Germany.
Correspondence to Michael Buerke, MD, Department of Medicine III, Martin-Luther-University, Ernst-Grube-Str. 40, 06120 Halle, Germany. E-mail michael.buerke{at}medizin.uni-halle.de
| Abstract |
|---|
|
|
|---|
-toxininduced increase in leukocyte-endothelial interactions during exotoxemia.
Methods and Results The effects of simvastatin on leukocyte-endothelial cell interactions were observed by intravital microscopy in the rat mesenteric microcirculation. Simvastatin (50 or 100 µg/kg) was administered 18 hours before the study. Activation of microcirculation was induced by bolus administration of 40 µg/kg S aureus
-toxin. Exotoxemia resulted in a significant and time-dependent increase in leukocyte rolling, adherence, and transmigration of leukocytes as well as P-selectin expression on the intestinal vascular endothelium. Pretreatment with simvastatin significantly inhibited exotoxin-induced leukocyte rolling from 71±10 to 14±4.7 cells/min (P<0.01) and adherence from 14±3.5 to 0.4±0.2 cells (P<0.01). In addition, simvastatin pretreatment significantly inhibited transmigration of leukocytes from 10.5±1.2 to 4.2±0.9 (P<0.05) cells. Immunohistochemical detection of endothelial cell adhesion molecule P-selectin showed a 50% decrease in endothelial cell surface expression after simvastatin treatment. Furthermore, simvastatin treatment resulted in enhanced expression of endothelial cell NO synthase III in the intestinal microcirculation.
Conclusions These results demonstrate that simvastatin interferes with exotoxin-induced leukocyte-endothelial cell interactions, which may be relevant in various infectious diseases. Statin treatment may offer a new therapeutic strategy for these clinical conditions.
Key Words: statins endothelium inflammation microcirculation
| Introduction |
|---|
|
|
|---|
See p 2041
In this context, P-selectin and intracellular adhesion molecule-1 are upregulated on endothelial cells after activation with proteinaceous exotoxin (ie, Staphylococcus aureus
-toxin and Escherichia coli hemolysin).6
-Toxin, prototype of a pore-forming exotoxin, is the major cytotoxin of Staphylococcus aureus.79 Purified
-toxin is known to provoke cardiovascular collapse in intact animals or isolated hearts, causing strong activation and mediator release of various cell types.1014
The discovery of the 3-hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the 1980s and their clinical use as therapeutic agents15 has resulted in widespread treatment of hyperlipidemia and coronary artery disease. The major mechanism of the HMG-CoA reductase inhibitors (ie, simvastatin, lovastatin, and pravastatin), commonly referred to as statins, is the inhibition of cholesterol synthesis in the liver by blocking the conversion of HMG-CoA to mevalonate, the rate-limiting step in cholesterol biosynthesis. Recently, statins have been reported to protect endothelial function in the absence of hypercholesterolemia in isolated endothelial cells16 and in intact organisms.17,18
Because of the important role of leukocyte-endothelium interaction during inflammatory states,19 our study was designed to investigate the effects and mechanisms of the prototype statin simvastatin on leukocyte-endothelial cell interactions in vivo, using exotoxemia for mimicking septic conditions.
| Methods |
|---|
|
|
|---|
A loop of ileal mesentery was exteriorized through the midline incision and placed in a temperature-controlled fluid-filled plexiglass chamber for observation of the mesenteric microcirculation via intravital microscopy, as described previously.20 The ileum and mesentery were superfused throughout the experiment with a buffered saline solution warmed to 37°C. A microscope and a x40 water immersion lens (Zeiss-Axioplan) were used to visualize the mesenteric microcirculation and the mesenteric tissue. The image was projected by a CCD video camera onto a high-resolution monitor, and the image was recorded with a videocassette recorder. All images were then analyzed using computerized imaging software. Red blood cell velocity was determined online using an optical Doppler velocimeter (Microcirculation Research Institute) to calculate shear rates. This method gives an average red blood cell velocity, which is digitally displayed and allows calculation of shear rates [formula: shear rate g=8(Vmean/D); (Vmean=Vrbc/1.6, red blood cell velocity (V), venular diameter (D)].21
The rats were allowed to stabilize for 20 to 30 minutes after surgery. After stabilization, a 30- to 45-µm-diameter postcapillary venule was chosen for observation. The number of rolling and adherent leukocytes was determined offline by playback analysis of videotape. Leukocytes were considered to be rolling if they were moving at a velocity significantly slower than the red blood cells and expressed as the number of cells moving past a designated point per minute. A leukocyte was judged to be adherent if it remained stationary for >30 seconds.22 Adherence is expressed as the number of leukocytes adhering to the endothelium per 100 µm of vessel length. To quantify the number of transmigrated leukocytes, the tissue area adjacent to the 100-µm length of postcapillary venule over a distance of 20 µm from the vessel wall was used. The number of extravasated leukocytes was counted and normalized with respect to this area.
Immunolocalization of P-Selectin and Endothelial Cell NO Synthase in the Microvasculature
After completion of intravital microscopy, the immunohistochemical localization of P-selectin was determined in ileal samples, as described above.20 A segment of ileum was isolated from the intestine and fixed in 4.5% paraformaldehyde in PBS (pH 7.0). After dehydration, the sections were embedded and cut to 5-µm tissue sections. Immunohistochemical localization of P-selectin was accomplished using the avidin/biotin immunoperoxidase technique (Vectasin ABC Reagent, Vector Laboratories), using a monoclonal antibody against P-selectin (Pharmingen, Hamburg, Germany) exposed on the endothelial cell surface and expressed as percentage of positively staining venules. Similarly, immunohistochemical analysis of constitutive endothelial cell NO synthase (NOS III) was performed using a monoclonal antibody against constitutive ecNOS (NOS III, Pharmingen, Hamburg, Germany) expressed in the vascular endothelium. Because ecNOS is expressed constitutively, we used an intensity score from 0 to 5, where 0 expressed no staining and 5 expressed intense staining. Intensity was calculated from sections of the vehicle- and simvastatin-treated intestinal tissue.
Experimental Protocols
Rats were randomly divided into one of the following groups: (a) buffer-superfused mesenteries (control group); (b) rats injected with 50 µg/kg simvastatin in 1.0 mL 0.9% NaCl IP 18 hours before intravital microscopy; (c) rats injected with 100 µg/kg simvastatin as above; or (d) rats injected with 1.0 mL of 0.9% NaCl as above. A baseline recording was made to establish basal values for leukocyte rolling, adherence, and transmigration (time 0). Immediately thereafter, in groups b, c, and d, 40 µg/kg S aureus
-toxin (provided by Professor Bhakdi, Mainz, Germany, isolation was performed as described previously23) or its vehicle (NaCl 0.9%) were administered systemically as bolus injection. Video recordings were made at 30, 60, 90, and 120 minutes after initiation of exotoxemia for quantification of leukocyte rolling, adherence, and transmigration.
In a second set of experiments, rats were anesthetized with pentobarbital, and a polyethylene catheter was inserted in the left carotid artery. Mean arterial blood pressure and heart rate were recorded continuously over 4 hours. Rats were randomly divided into one of two groups: vehicle rats treated with 40 µg/kg S aureus
-toxin or rats pretreated with 100 µg/kg simvastatin in 1.0 mL 0.9% NaCl IP 18 hours before intravenous injection of 40 µg/kg S aureus
-toxin. Hemodynamic monitoring and survival rate were determined. Administration of 100 µg/kg simvastatin intraperitoneally did not change serum cholesterol or subtype (LDL or HDL) levels.
Data Analysis
All data are presented as mean±SEM. Data were compared by ANOVA using post hoc analysis with Fishers corrected t test. P
0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
-toxin injection only slightly diminished MABP and increased heart rate, but this effect was statistically not significant (Table). Similar, no significant differences were observed for the shear rates in the different groups (range, 630±50 to 720±60 s-1). Thus, the adhesive interactions observed between leukocytes and endothelial cells were not attributable to any hemodynamic factors.
|
A low baseline number of rolling leukocytes was observed in the mesenteric microvasculature for all experimental groups. After infusion of vehicle, PMN rolling and adherence did not change significantly. However, infusion of S aureus
-toxin (40 µg/kg) resulted in a rapid and significant increase in leukocyte rolling compared with buffer-control animals (Figure 1). The increase in leukocyte rolling was statistically significant 30 minutes after injection of S aureus
-toxin and reached values from 7- to 8-fold above baseline values at 120 minutes (P<0.01). The increase in leukocyte adherence was statistically significant 30 minutes after toxin administration (P<0.05 versus control rats), reaching values from 6- to 7-fold above baseline values at 120 minutes (P<0.01) (Figure 2).
|
|
Pretreatment with simvastatin significantly inhibited both leukocyte rolling and adherence by virtually almost complete inhibition after
-toxin administration. The effects of simvastatin on the time course of S aureus
-toxininduced rolling and adherence are shown in Figures 1 and 2. Administration of 50 and 100 µg/kg simvastatin significantly inhibited the number of rolling and adherent leukocytes in a dose-dependent manner. Furthermore, the range of rolling velocity (10 to 100 µm/s) among the different groups did not change. Interestingly, when pretreatment with simvastatin was performed just 1 hour before exotoxin challenge, no protective effects could be observed. Similarly, intravenous administration of the P-selectinneutralizing monoclonal antibody humanized PB1.3 (1 mg/kg) significantly decreased leukocyte rolling and adherence after S aureus
-toxin challenge similar to the degree of simvastatin-treated animals (68.4±9.3 versus 19.4±4.2 rolling PMN, 16.3±2.6 versus 2.9±1.2 adhering PMN, P<0.05). Furthermore, we could confirm the reduction of cell-cell interaction when animals were pretreated with simvastatin and mesenterium was superfused with thrombin.
Figure 3 depicts typical video image of increased leukocyte-endothelium interaction after administration of
-toxin (Figure 3A) and is decreased after pretreatment with simvastatin (Figure 3B).
|
In rats receiving vehicle injection, very few transmigrated leukocytes were observed at 120 minutes in the mesenteric extravascular space (Figure 4). However, in rats injected with S aureus
-toxin (40 µg/kg), the number of migrated leukocytes in the surrounding tissue was markedly increased 4- to 5-fold. Pretreatment with 100 µg/kg simvastatin 18 hours before study significantly attenuated the number of extravasated leukocytes after toxin injection (10.5±1.2 to 4.2±0.9, P<0.05). In histological analysis, we predominantly observed extravasation of neutrophils at the site of venules and only few lymphocytes and eosinophils.
|
When we observed the hemodynamic effects in the second set of experiments over a longer time period (ie, 4 hours), we were able to see a decrease in blood pressure that started to occur after 120 minutes and was profound in some animals. Three of the 7 vehicle animals (42%) treated with S aureus
-toxin survived the 4-hour observation period (mean survival time, 170±15 minutes), whereas all of the rats pretreated with simvastatin survived the whole 4-hour observation period (7 of 7, 100%, P<0.05).
Immunolocalization of P-Selectin in the Rat Mesenteric Microvasculature
Localization of P-selectin was accomplished using a modified avidin-biotin immunoperoxidase technique. The percentages of venules staining positive for P-selectin in ileal sections from control rats were consistently low, in the range of 10% (Figure 5). S aureus
-toxin infusion resulted in a significant increase of P-selectin expression up to 50% positive vessels. The increase in expression of P-selectin on ileal venules was significantly suppressed by pretreatment with simvastatin (P<0.05).
|
Immunolocalization of ecNOS in the Rat Mesenteric Microvasculature
Positive ecNOS staining was observed on the vascular endothelium in the rat intestine of vehicle rats. Immunolocalization of ecNOS was seen for almost the whole circumference of the vessels consistently with low intensity (1.7±0.4 intensity score). Pretreatment with simvastatin resulted in significant intensity increase of ecNOS within the vasculature (3.5±0.7, intensity score, P<0.05) (Figure 6). Interestingly, treatment with S aureus
-toxin did not change immunohistochemical-analyzed ecNOS expression.
|
| Discussion |
|---|
|
|
|---|
-toxin challenge on leukocyte-endothelium interaction, to relate these changes to the expression of cell-adhesion molecules, and to determine the effects of simvastatin, a HMG-CoA reductase inhibitor (statin), on the exotoxin-induced abnormalities. To our knowledge, our results are the first to demonstrate a protective effect of a statin under conditions of acute inflammation induced by an exotoxin within the microcirculation. In particular, we provide strong evidence that simvastatin is able to attenuate enhanced leukocyte-endothelium interaction after S aureus
-toxin administration. Pore-forming S aureus
-toxin9 is known to provoke cardiovascular collapse as well as inflammatory acctivation.1,10,1214
HMG-CoA reductase inhibitors are used clinically for lowering hypercholesterolemia because of their inhibitory effect on hepatic biosynthesis of cholesterol at the mevalonate step. Several animal and human studies24,25 indicate improved endothelial function associated with a lowering of serum cholesterol. Recently, the statins have been reported to preserve endothelial function in the absence of hypercholesterolemia in isolated endothelial cells16 and in intact organisms.18,20,26 Because of the important role of endothelial function during inflammatory states, our study was designed to investigate the effects and mechanisms of a prototype statin on leukocyte-endothelial cell interaction in vivo after bacterial toxin challenge (ie, S aureus
-toxin).
The present study clearly demonstrates that simvastatin, given 18 hours before toxin administration in pharmacologic concentrations (0.1 mg/kg translated to
10 mg in humans), is able to attenuate exotoxin-induced leukocyte-endothelial cell interactions, most probably via a P-selectindependent mechanism. Interestingly, 1-hour pretreatment with simvastatin did not demonstrate this protective effect. These anti-adhesive effects may not be explained by the cholesterol-lowering effects of simvastatin, because in our model, cholesterol levels did not change. This might point toward other mechanisms of HMG-CoA reductase inhibitors. Moreover, these effects occurred without significant changes of venular shear rates and the range of rolling velocity among the different groups. Furthermore, the anti-inflammatory effect of simvastatin on exotoxin challenge could be translated to significant improvement of survival.
Recent studies on leukocyte and endothelial adhesion molecules involved in the acute inflammatory response indicate a complex pattern of leukocyte-endothelium interaction that precedes emigration of leukocytes from the vasculature into the surrounding tissue. Leukocyte endothelium interaction is known to be a multistep process involving sequential activation of specific cell adhesion molecules. An important early event during these conditions is endothelial dysfunction.14 This is characterized by reduced synthesis and release of NO, an important endothelium-derived substance involved in the inhibition of platelet aggregation, attenuation of neutrophil adherence, and maintenance of microvascular integrity.27 Moreover, Davenpeck et al28 demonstrated that reduced endogenous NO synthesis results in the upregulation of P-selectin on the endothelial cell surface of mesenteric microvessels. In support of this view, P-selectin upregulation can be decreased by administration of a NO donor.29 In this regard, statins have been shown to increase expression of endothelial NOS, leading to enhanced release of NO, which could be responsible for nonlipid-lowering actions of the statins.16 In this line, simvastatin treatment of mice increased the catalytic activity of calcium-dependent NOS by 2- to 3-fold.30 Moreover, statins were found to significantly increase NO generation by 2- to 3-fold (measured by direct NO electrode).31 Similarly, we were able to observe enhanced ecNOS expression within the intestinal vasculature after simvastatin treatment.
P-selectin, a member of the selectin family of adhesion molecules, is believed to play a significant role in the initial phase of leukocyte capture, which is rolling of leukocytes along the vascular endothelial surface.2,28 PMN rolling serves to tether the neutrophil to the activated endothelium, thus bringing the neutrophil in closer contact with the endothelial cells, allowing firm adherence to occur.3,32 Once firmly adhered through the interaction of the ß2-integrins with their endothelial counter-receptor, intercellular adhesion molecule-1, leukocytes can then undergo additional activation, migrate across the endothelium, and release free radicals and proteolytic enzymes with subsequent tissue injury.5,33 It has been previously shown that lovastatin decreases CD11b expression and CD11b-dependent adhesion of monocytes to endothelium in humans, independent of cholesterol-lowering effects.34 Additionally, Lefer et al31 demonstrated that simvastatin downregulates CD18 on stimulated polymorphonuclear cells in normocholesterolemic rats. However, S aureus
-toxin is known to be a weak activator of leukocytes. Nevertheless, this also could contribute to the observed endothelium-protective effects in the present study occurring independently of the well-known lipid-lowering effects of the HMG-CoA reductase inhibitors.
Previously, Buerke et al14 demonstrated endothelium dysfunction and enhanced PMN adherence to the vascular endothelium after stimulation with S aureus
-toxin. An interesting aspect of this study was the inhibitory role of a PAF receptor antagonist in PMN-induced vasocontraction and endothelial dysfunction. PAF is coexpressed with P-selectin on the endothelial surface after stimulation with thrombin, oxygen-derived radicals, or Staphylococcus aureus
-toxin.12 Lorant et al3 demonstrated that PAF coexpressed with P-selectin on the endothelial surface facilitates the subsequent activation of PMNs after P-selectinmediated leukocyte rolling. Therefore, it is possible that simvastatin interferes with PAF-mediated activation as an additional beneficial effect.
Furthermore, simvastatin may also inhibit the release of potent PMN chemoattractants and cytokines. Activated neutrophils produce proinflammatory modulators, including tumor necrosis factor-
and interleukin-6, which serve to activate additional neutrophils and propagate inflammation. In this regard, it has been demonstrated that simvastatin exerts marked anti-inflammatory effects via reduction of tumor necrosis factor-
and interleukin-6 levels.35 This property of simvastatin may be an additional mechanism by which statins afforded anti-inflammatory effects in vivo.
In conclusion, this is the first study to demonstrate in vivo that administration of simvastatin, a HMG-CoA reductase inhibitor, inhibits leukocyte rolling, adherence, and transmigration in acute inflammatory states induced by the exotoxin S aureus
-toxin. This effect was found to be mediated via decreased upregulation of P-selectin on endothelial cells as well as enhanced NOS III expression within the vasculature. These observations may open a new field of pharmaceutical use of statins, such as prevention of tissue damage mediated in states of infectious diseases.
| Acknowledgments |
|---|
Received May 30, 2002; revision received July 18, 2002; accepted July 18, 2002.
| References |
|---|
|
|
|---|
-toxin potently induce neutrophil adhesion to cultured human endothelial cells. J Immunol. 1996; 157: 41334140.[Abstract]
-Toxin of Staphylococcus aureus. Microbiol Rev. 1991; 55: 733751.
-toxin. EMBO J. 1996; 15: 18571864.[Medline]
[Order article via Infotrieve]
-toxin. J Immunol. 1997; 159: 19091916.[Abstract]
-toxin. Thromb Res. 1992; 67: 243252.[CrossRef][Medline]
[Order article via Infotrieve]
-toxin provokes coronary vasoconstriction and loss in myocardial contractility in perfused rat hearts: role of thromboxane generation. Circulation. 2000; 101: 7885.
toxin mediates polymorphonuclear leukocyte induced vasocontraction and endothelial dysfunction. Shock. 2002; 17: 3035.[CrossRef][Medline]
[Order article via Infotrieve]
-toxin: production of functionally intact, site-specifically modifiable protein by introduction of cysteine at positions 69, 130, and 186. J Biol Chem. 1993; 268: 1195911962.Related Article:
This article has been cited by other articles:
![]() |
F. Gao, L. Linhartova, A. McD. Johnston, and D. R. Thickett Statins and sepsis Br. J. Anaesth., March 1, 2008; 100(3): 288 - 298. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Suzuki, Z.-G. Jin, D. F. Meoli, T. Matoba, and B. C. Berk Cyclophilin A Is Secreted by a Vesicular Pathway in Vascular Smooth Muscle Cells Circ. Res., March 31, 2006; 98(6): 811 - 817. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Erkkila, M. Jauhiainen, K. Laitinen, K. Haasio, T. Tiirola, P. Saikku, and M. Leinonen Effect of Simvastatin, an Established Lipid-Lowering Drug, on Pulmonary Chlamydia pneumoniae Infection in Mice Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3959 - 3962. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Pleiner, G. Schaller, F. Mittermayer, S. Zorn, C. Marsik, S. Polterauer, S. Kapiotis, and M. Wolzt Simvastatin Prevents Vascular Hyporeactivity During Inflammation Circulation, November 23, 2004; 110(21): 3349 - 3354. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Miyahara, J. Kiryu, K. Yamashiro, K. Miyamoto, F. Hirose, H. Tamura, H. Katsuta, K. Nishijima, A. Tsujikawa, and Y. Honda Simvastatin Inhibits Leukocyte Accumulation and Vascular Permeability in the Retinas of Rats with Streptozotocin-Induced Diabetes Am. J. Pathol., May 1, 2004; 164(5): 1697 - 1706. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M Ridker and on behalf of the JUPITER Study Group Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein: Rationale and Design of the JUPITER Trial* Circulation, November 11, 2003; 108(19): 2292 - 2297. [Full Text] [PDF] |
||||
![]() |
D. J. Kereiakes Adjunctive Pharmacotherapy before Percutaneous Coronary Intervention in Non-ST-Elevation Acute Coronary Syndromes: The Role of Modulating Inflammation Circulation, October 21, 2003; 108(90161): III-22 - 27. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Balduini, E. Mazzoni, S. Carloni, M. G. De Simoni, C. Perego, L. Sironi, and M. Cimino Prophylactic but Not Delayed Administration of Simvastatin Protects Against Long-Lasting Cognitive and Morphological Consequences of Neonatal Hypoxic-Ischemic Brain Injury, Reduces Interleukin-1{beta} and Tumor Necrosis Factor-{alpha} mRNA Induction, and Does Not Affect Endothelial Nitric Oxide Synthase Expression Stroke, August 1, 2003; 34(8): 2007 - 2012. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Lefer Statins as Potent Antiinflammatory Drugs Circulation, October 15, 2002; 106(16): 2041 - 2042. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |